MeSH tree: C15.604.515
Scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved ...
Jul 28, 2026
0
12
Why do children with lymphoid leukemia face markedly different mortality rates depending on where they live in Brazil? In a collaboration between researchers at LMU and the Federal University of Rio de Janeiro (UFRJ), trends ...
Jul 23, 2026
0
4
A new Northwestern Medicine study has discovered how radiotherapy alters the immune environment within cutaneous T-cell lymphoma (CTCL) tumors, according to findings published in the Journal of the American Academy of Dermatology.
Jul 7, 2026
0
3
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists ...
Jul 3, 2026
0
6
A new study led by researchers at the University of Hawaiʻi Cancer Center found that at least $230 million was spent on cancer care delivered outside Hawaiʻi between 2021 and 2023, highlighting the significant financial impact ...
Jul 3, 2026
0
7
Survivors of hematologic cancers are at high risk of developing cardiovascular disease (CVD), according to a study published online June 22 in BMC Cancer.
Jun 30, 2026
0
4
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy ...
Jun 25, 2026
0
13
UK media celebrity Jeremy Clarkson this week revealed he has been diagnosed with an aggressive form of prostate cancer.
Jun 18, 2026
0
15
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or difficult-to-treat blood cancers.
Jun 15, 2026
0
4
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
Jun 15, 2026
0
4
